| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| Targets |
p2x1 Receptor P2X3 Receptor P2X4 Receptor P2X7 Receptor
|
|---|---|
| ln Vitro |
BzATP (10-1000 μM; 24 h) stimulates U87 and U251 glioma cell migration and proliferation [3]. In human glioma cells, BzATP (100μM; 6-48h) promotes the production of P2X7R protein [3].
|
| ln Vivo |
BzATP (5 mg/kg) dramatically increased P2X7R expression in the colon following cecal ligation and puncture (CLP) induction as compared to the control and sham operation groups [4].
|
| Cell Assay |
Cell Proliferation Assay[3]
Cell Types: U87 and U251 glioma cells Tested Concentrations: 5, 10, 50, 100, 500 and 1000 μM Incubation Duration: 2, 6, 12, 24, 48 and 72 hrs (hours) Experimental Results: The proliferation of U87 and U251 glioma cell lines was Dramatically increased in the presence of 10-1000 uM and 100-1000 μM, respectively. The peak of cell proliferation of both U87 and U251 cell lines was at 100 μM. The optimal incubation time is 24 hrs (hours) in both U87 and U251 cells lines. Western Blot Analysis[3] Cell Types: U87 and U251 glioma cells Tested Concentrations: 100 μM Incubation Duration: 6-48 hrs (hours) Experimental Results: Induced the upregulation of P2X7R. |
| Animal Protocol |
Animal/Disease Models: Male 2-month-old C57BL/6 mice (each weighing between 20 and 25 g)[4]
Doses: 5 mg/kg Route of Administration: Injected through the intraperitoneal (ip)route Experimental Results: At 48 hrs (hours), mice in the treated group and The control group demonstrated mortalities of 91% and 86%, respectively. |
| References |
[1]. B R Bianchi, et al. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol. 1999 Jul 2;376(1-2):127-38.
[2]. Mark T Young, et al. Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Mol Pharmacol. 2007 Jan;71(1):92-100. [3]. Zhenhua Ji, et al. Involvement of P2X 7 Receptor in Proliferation and Migration of Human Glioma Cells. Biomed Res Int. 2018 Jan 9;2018:8591397. [4]. Xiuwen Wu, et al. Systemic blockade of P2X7 receptor protects against sepsis-induced intestinal barrier disruption. Sci Rep. 2017 Jun 29;7(1):4364. |
| Molecular Formula |
C24H24N5O15P3.C18H45N3
|
|---|---|
| Molecular Weight |
1018.97
|
| Solubility (In Vitro) |
H2O :~50 mg/mL (~49.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (98.14 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9814 mL | 4.9069 mL | 9.8138 mL | |
| 5 mM | 0.1963 mL | 0.9814 mL | 1.9628 mL | |
| 10 mM | 0.0981 mL | 0.4907 mL | 0.9814 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
